
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas Inc has showcased promising results in its clinical trials, particularly highlighting the statistically significant improvements in median progression-free survival (mPFS) for vepdegestrant (vepdeg) in ESR1 mutant populations, which offers a competitive edge compared to existing therapies. The Company's data suggests a potential for vepdeg to achieve over four months of mPFS, positioning it favorably against other treatments, and indicates a safe profile with no dose-limiting toxicities. With these advancements, Arvinas is well-poised for differentiation in the biopharmaceutical marketplace, underscoring its commitment to addressing unmet medical needs and enhancing patient outcomes.
Bears say
Arvinas Inc faces several challenges that contribute to a negative outlook on its stock. The lack of demonstrated benefit in the intention-to-treat population raises concerns about the potential for a restricted product label, which could hinder market differentiation and delay revenue generation. Additionally, significant competitive risks exist around both the approval timelines for its therapies and their ability to effectively compete against current and future treatments, further dampening investor confidence in the company's commercial prospects.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares